greeksoup/ stock research

Novavax (NVAX) Q4 FY2023 earnings: revenue $291 million, down 18.5% on the year

Novavax Inc. (NVAX) reported revenue of $291 million for Q4 FY2023, the quarter ended 31 December 2023, down 18.5% on the same quarter a year earlier. Net income was -$178 million, and diluted earnings per share $-1.44. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2024.

Revenue$291 milliondown 18.5%
Net income-$178 million
Diluted EPS$-1.44
QuarterQ4 FY2023ended 31 December 2023

The quarter, against the one before and a year earlier

LineQ4 FY2023Q3 FY2023Q4 FY2022Change on the year
Revenue291187357-18.5%
Cost of revenue15598.9182-14.7%
Gross profit13688.1176-22.4%
Gross margin46.8%47.1%49.1%
Research and development165106258-36.1%
Operating income-184-126-244n/a
Operating margin-63.0%-67.2%-68.2%
Interest expense4.12.94.6-10.5%
Pre-tax income-177-131-185n/a
Income tax1.7-0.7-2.3n/a
Net income-178-131-182n/a
Net margin-61.2%-69.9%-51.0%
Diluted EPS-$1.44-$1.26-$2.30n/a
$ million except per share.
Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ4 FY2023Q3 FY2023Q4 FY2022Change on the year
Operating cash flow-177-39.7-118n/a
Capital expenditure8.818.223.0-61.6%
Free cash flow-186-57.8-141n/a
Free cash flow margin-63.7%-30.9%-39.4%
Cash from investing-9.1-18.4-22.1n/a
Cash from financing100197191-47.6%
Depreciation and amortisation10.611.37.2+46.3%
Share-based compensation15.720.827.8-43.6%
Diluted shares, weighted124m103m78m+58.2%
Shares outstanding at period end140m119m86m+62.1%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ4 FY2023Q3 FY2023Q4 FY2022Change on the year
Shareholders' equity-717-678-634n/a
Debt168168491-65.8%
Operating lease liabilities28.6n/a50.1-42.9%
Finance lease liabilities55.953.231.2+79.0%
Other liabilities2,2622,1152,320-2.5%
Total liabilities and equity1,7971,6572,259-20.4%
Fixed assets306301294+3.9%
Goodwill127124126+0.9%
Investments0.0n/an/an/a
Cash and equivalents5696511,337-57.5%
Inventory41.769.636.7+13.7%
Other assets754512465+62.3%
Total assets1,7971,6572,259-20.4%

Questions

What was Novavax's revenue in Q4 FY2023?

Novavax (NVAX) reported revenue of $291 million for Q4 FY2023, the quarter ended 31 December 2023, down 18.5% on the same quarter a year earlier.

How much did Novavax earn in Q4 FY2023?

Net loss for Q4 FY2023 was $178 million, and the diluted loss per share $1.44.

When did Novavax report Q4 FY2023 results?

Novavax filed its 10-K for the year that ended with the quarter on 28 February 2024; the fourth quarter is the year less the first three.

Quarterly results, the last 20 quarters

Q3 FY2021Q4 FY2021 *Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue17922270418673535781.042418729193.941584.588.366723970.414714056.7
Cost of revenue0.00.015.227143518234.155.898.915559.246.260.636.714.115.321.522.130.714.2
Gross profit179222689-85.230017646.936988.113634.636923.951.665322448.912510942.5
Gross margin100%100%98%-46%41%49%58%87%47%47%37%89%28%58%98%94%69%85%78%75%
R&D40896338329030425824721910616592.710787.210488.979.298.375.995.570.7
SG&An/an/an/an/an/an/an/an/an/an/an/an/a70.7n/a48.143.631.734.128.826.7
Operating income-307-825209-483-127-244-31355.5-126-184-145161-134-131516101-17814.2-15.4-54.9
Operating margin-172%-371%30%-260%-17%-68%-386%13%-67%-63%-154%39%-159%-148%77%42%-253%10%-11%-97%
Interest expense5.25.14.96.24.24.64.33.12.94.14.14.14.27.65.75.55.55.84.95.7
Pre-tax income-316-830206-509-166-185-29357.9-131-177-145165-122-73.6520107-20317.9-8.5-51.7
Tax raten/an/a1%n/an/an/an/a-0%n/an/an/a1%n/an/a0%1%n/a2%n/an/a
Net income-322-846203-510-169-182-29458.0-131-178-148162-121-81.0519107-20217.5-9.5-53.4
Net margin-180%-381%29%-275%-23%-51%-363%14%-70%-61%-157%39%-144%-92%78%45%-287%12%-7%-94%
Diluted EPS-$4.31-$11.33$2.56-$6.53-$2.15-$2.30-$3.41$0.58-$1.26-$1.44-$1.05$0.99-$0.76-$0.51$2.93$0.62-$1.25$0.11-$0.06-$0.32
Operating cash flow-142-342-88.5-171-38.7-118-326-172-39.7-177-83.6314-145-173-186-127108-39.5-32.4-72.8
Capital expenditure12.216.416.824.624.623.019.87.018.28.86.92.91.41.91.20.22.02.11.30.6
Free cash flow-154-359-105-195-63.3-141-345-179-57.8-186-90.4311-146-175-187-128106-41.6-33.7-73.4
Shares outstanding75m76m78m78m78m86m86m94m119m140m140m160m160m160m162m162m162m163m164m165m
Filing10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-K for the period ended 31 December 2023, filed 28 February 2024: the filing.